Global Scientific and Academic Research Journal of Multidisciplinary Studies
ISSN: 2583-4088 (Online)
Frequency: Monthly
Published By GSAR Publishers
Journal Homepage Link- https://gsarpublishers.com/journals-gsarjms-home/

BROAD-SPECTRUM ANTIVIRALS: CURRENT ADVANCES, MECHANISMS, AND PANDEMIC PREPAREDNESS

By

Oluwapelumi S. Ogunlusi[1], Adebayo E. Sopeju[1], Ebere E. Ayogu[1], Segun S. Opoola[1], Ishioma Chibuogwu[1], Ojomah F. Eneojo[1]

[1]Department of Virology, Faculty of Basic Medical Sciences, College of Medicine, University of Ibadan

Article History

Received: 15/02/2026
Accepted: 26/02/2026
Published: 28/02/2026

Vol – 5 Issue –2

PP: - 29-42

Abstract

Emerging infectious diseases present an escalating global health threat, with pandemic-scale outbreaks occurring at an estimated frequency of every 33-50 years. Traditional antiviral development focused on virus-specific compounds has proven inadequate for responding to novel pathogens, as demonstrated by the rapid emergence of drug-resistant SARS-CoV-2 variants and the persistent vulnerability of populations lacking therapeutics for hundreds of known human viruses.

This comprehensive review examines broad-spectrum antivirals as a paradigm shift in pandemic preparedness and therapeutic strategy. We synthesize current knowledge across two primary mechanistic classes: Direct-Acting Antivirals (DAAs) targeting conserved viral replication machinery through viral entry inhibitors, polymerase inhibitors, and protease inhibitors; and Host-Targeting Antivirals (HTAs) exploiting conserved cellular dependencies including kinase inhibitors, metabolic pathway modulators, and immune system enhancers.

The review further explores natural product-derived antivirals from plants, marine organisms, and fungi as underexploited sources of broad-spectrum compounds with multi-target mechanisms. Integration of artificial intelligence, machine learning, and computational chemistry has substantially accelerated compound discovery and target identification. Clinical pipelines now include diverse mechanistic classes with Emergency Use Authorization pathways enabling rapid deployment. However, critical challenges persist, including achieving both potency and selectivity, managing antiviral resistance through combination therapy and surveillance, navigating regulatory frameworks for prophylactic use, and overcoming economic barriers to development.

Recommendations include government-funded mechanisms for broad-spectrum development, adaptive clinical trial designs, intellectual property incentives, manufacturing surge capacity, and international collaboration frameworks. This review demonstrates that broad-spectrum antiviral development has transitioned from theoretical concept to clinical reality, with substantial potential to reduce pandemic morbidity and mortality while minimizing costly confinement measures and enabling rapid first-line defense during the critical early stages of novel pathogen emergence.

Keywords: *broad-spectrum antivirals, direct-acting antivirals, host-targeting antivirals, pandemic preparedness, antiviral resistance, viral therapeutics, drug discovery*

INTRODUCTION

The global landscape of viral threats demands a fundamental reimagining of antiviral therapeutic strategies. Traditional approaches, while successful for specific pathogens, have revealed critical limitations that broad-spectrum antivirals are uniquely positioned to address. The traditional paradigm of antiviral drug development has centered on the discovery and optimization of virus-specific therapeutic compounds designed to inhibit essential viral proteins or processes unique

*Corresponding Author: **Oluwapelumi S. Ogunlusi**

to individual pathogens [1]. However, this strategy has proven fundamentally inadequate for responding to emerging viral threats, particularly during pandemic scenarios. Most approved antiviral therapeutics target proteins encoded by a single virus, providing a narrow spectrum of coverage that limits scalability in crises. [2][3]

Furthermore, virus-specific antivirals are inherently susceptible to viral escape through mutation. Viruses, particularly RNA viruses, possess high mutation rates and can rapidly develop resistance to direct-acting antiviral (DAA) agents through the emergence of drug-resistance mutations. As observed with SARS-CoV-2, the rapid generation of new variants (such as Omicron, which harbors >30 amino acid substitutions in its spike protein, including at least 15 in the receptor-binding domain) has rendered many monoclonal antibodies and narrow-spectrum antivirals ineffective within months of their introduction [4]. This pattern of viral escape is not novel; it has been documented extensively in HIV therapy, hepatitis C virus treatment, and influenza management. Consequently, maintaining an effective arsenal of virus-specific therapeutics requires continuous redevelopment efforts, creating an unsustainable cycle of drug development in response to each new variant or viral species[5].

The development of traditional antivirals involves substantial economic investment and extended timelines. The mean expected capitalized cost of developing a new drug range from $314 million to $4.46 billion, with an average development period extending approximately 12 years from target discovery to regulatory approval [6]. This timeline is particularly problematic for pandemic preparedness, as waiting periods of over a decade render any preemptively developed drug obsolete or inappropriate for the next emerging threat. The burden is compounded by the fact that drug development failures account for a major portion of overall expected costs, and anti-infective drugs typically require large clinical trial populations, further inflating development expenses. [7,9]

The epidemiological landscape has shifted dramatically over the past five decades, with emerging infectious diseases appearing at an accelerating rate. The World Health Organization estimates that pandemics of the magnitude of COVID-19 or worse could occur every 33 to 50 years. Recent examples underscore this threat: Ebola virus outbreaks (2014-2016, 2018-2020), Zika virus emergence (2015-2016), Middle East Respiratory Syndrome coronavirus (MERS-CoV) intermittent cases, recurrent Nipah virus encephalitis outbreaks in Kerala, India (2018-2024), and the ongoing COVID-19 pandemic all occurred unexpectedly or with limited warning. Beyond pandemic potential, hundreds of viruses known to cause human disease lack effective therapeutics, leaving populations vulnerable when sporadic spillover events occur. [3,10]

The fundamental challenge is that, by definition, novel viruses are unknown entities. When a previously uncharacterized pathogen emerges (whether entirely novel or a zoonotic spillover from animals), the specific molecular characteristics required for virus-specific drug development are not yet elucidated. In this critical window, often weeks to months after initial detection, affected populations receive only supportive care while vaccines and virus-specific therapeutics are in development. Broad-spectrum antivirals would provide a first line of defense during this crucial period, reducing transmission, minimizing disease severity, and potentially preventing outbreaks from escalating to epidemic or pandemic proportions. Furthermore, broader therapeutic options could reduce the need for costly confinement measures (contact restrictions, business closures, travel bans), which the OECD estimated cost approximately $1.7 trillion in business revenue alone during the first month of COVID-19 confinement measures.[3]

1.1 Definition and Classification of Broad-Spectrum Antivirals

Broad-spectrum antivirals are defined as a class of molecules or compounds that target more than one virus, either within a single family or from multiple viral families, offering a proactive approach to combating both current and future viral threats [8]. Broad-spectrum antivirals can be classified into two fundamentally distinct mechanistic categories, each with different advantages, limitations, and development trajectories. Understanding this dichotomy is essential for contextualizing contemporary antiviral research and pandemic preparedness strategies.

Direct-Acting Antivirals (DAAs) represent the traditional approach to antiviral development, where compounds directly interact with viral proteins or genomic elements essential for viral replication and infection. This mechanistic approach includes viral polymerase inhibitors (such as nucleoside and nucleotide analogues), viral protease inhibitors, viral entry inhibitors targeting envelope proteins, and inhibitors of other viral enzymes critical to the viral life cycle. The primary advantage of DAAs is that they have been extensively developed and optimized over decades, resulting in highly potent compounds with well-characterized pharmacokinetics and clinical efficacy profiles. Examples include remdesivir (a nucleotide analogue targeting viral RNA-dependent RNA polymerase), boceprevir and telaprevir (protease inhibitors originally developed for hepatitis C), and monoclonal antibodies against viral surface proteins.[11,12]

Host-Targeting Antivirals (HTAs) represent a fundamentally different paradigm, targeting human cellular proteins and pathways that viruses exploit for their replication and transmission, rather than targeting viral components directly. These agents recognize that all viruses, despite their genetic and molecular diversity, depend upon conserved host cell machinery for essential functions: entry into cells, nuclear/cytoplasmic transport, protein synthesis, RNA processing, membrane dynamics, and immune modulation. By targeting these shared host factors, HTAs can potentially achieve broad-spectrum activity against multiple viruses with minimal development of resistance [4].

*Corresponding Author: **Oluwapelumi S. Ogunlusi**

Examples of HTAs include interferon-based therapies (which activate broad innate immune responses), cyclophilin inhibitors (which block cellular factors required for replication of multiple coronavirus genera), iminosugars like miglustat (which impair protein glycosylation essential for viral entry of coronaviruses, dengue, and influenza), and newly developed host protease inhibitors targeting cathepsin L and calpain-1 (dual-target inhibitors showing broad-spectrum activity against coronaviruses and other enveloped viruses). Additionally, lipid metabolism modulators such as propranolol have demonstrated activity against coronaviruses, dengue virus, and Zika virus by disrupting the SREBP1-TMEM41B metabolic cascade essential for viral replication. [13,14]

The categorization of broad-spectrum antivirals by their spectrum of activity reveals another crucial dimension in antiviral classification. The breadth of activity ranges from family-specific compounds (effective against multiple strains within a single viral family) to pan-antivirals (demonstrating activity across multiple, distantly related viral families) [15].

Family-specific antivirals exploit conserved molecular targets within viral families. For coronaviruses, this includes inhibitors targeting conserved proteases (such as the main protease Mpro or papain-like proteases), the RNA-dependent RNA polymerase (RdRp), or host factors specifically utilized by coronaviruses. Pan-coronavirus inhibitors have been identified targeting conserved regions of the spike S2 fusion subunit, viral proteases, and host proteases like cathepsin L and calpain-1, critical for coronavirus entry [16]. Family-specific antivirals against other viral families include influenza polymerase inhibitors like favipiravir (T-705), which demonstrates broad activity across influenza subtypes and related orthomyxoviruses, and filovirus-targeting compounds like remdesivir, which was originally developed against the Ebola virus but subsequently shown to have activity against multiple coronavirus species. [17,18]

Pan-antivirals (inter-family antivirals) demonstrate activity across viruses from multiple families and represent the most ambitious goal of broad-spectrum antiviral development. These are achievable through several mechanisms: (1) nucleoside analogues that induce viral lethal mutagenesis or chain termination through incorporation into viral RNA, circumventing the requirement for family-specific target knowledge (examples include ribavirin, remdesivir, and favipiravir); (2) host-targeting approaches that exploit cellular vulnerabilities common to diverse viruses (such as lipid metabolism pathways or proteasome function); and (3) structural mimicry approaches, such as synthetic carbohydrate receptors that target viral glycans present on diverse enveloped viruses including SARS-CoV-2, Nipah, Hendra, Ebola, and Marburg viruses.[20]

The distinction between family-specific and pan-antivirals carries important implications for therapeutic deployment. Family-specific antivirals can be developed with detailed knowledge of one viral family and can exploit highly optimized targets, potentially achieving greater potency and selectivity. However, they remain limited to a defined subset of viral pathogens. Pan-antivirals, while potentially less potent against individual viruses, offer insurance value against unknown emerging threats. Ideally, comprehensive pandemic preparedness would involve the development of both family-specific antivirals for known high-risk families (coronaviruses, influenza viruses, filoviruses, henipaviruses) and broader-spectrum agents deployable at the outset of novel pathogen emergence.[19]

1.2 Historical Context and Evolution

The history of broad-spectrum antivirals extends back further than many appreciate, with early discoveries revealing both the promise and profound limitations of this approach. The first antiviral agent approved for clinical use was idoxuridine, discovered in 1963 and initially developed during research aimed at anticancer compounds rather than through targeted antiviral design. However, idoxuridine's activity was limited to herpes simplex virus (HSV) and related herpesviruses, providing insufficient breadth for pandemic preparedness.[21]

The development of interferon (IFN) represents one of the earliest successful host-directed antiviral approaches. Interferons are cytokines produced by infected cells that activate innate immune responses and induce an antiviral state through interferon-stimulated gene expression. Interferon-alpha was initially approved for hepatitis C treatment in 1991, achieving a dismal cure rate of only 6% when used as monotherapy. Despite this limitation, interferons demonstrated true broad-spectrum activity, subsequently being approved against hepatitis B virus and human papillomavirus infections [22,23]. However, interferon therapy is hampered by substantial side effects, including flu-like syndrome, hematologic abnormalities, depression, and, in some cases, neutralizing anti-interferon antibody production. Furthermore, many patients fail to respond (patient unresponsiveness rates are substantial), and the mechanism is partly immunomodulatory rather than direct antiviral, complicating its use in severe viral infections where dysregulated immune responses contribute to pathology. [24]

The discovery of ribavirin in 1970 by researchers at ICN Pharmaceuticals (now Valeant) marked a major advance in broad-spectrum antiviral development. Ribavirin, a guanosine analogue with an unconventional triazole base, demonstrated remarkable activity *in vitro* against both DNA and RNA viruses, a spectrum unprecedented for small-molecule antivirals. Its broad-spectrum antiviral activity was reported in 1972, and the aerosol form was approved in 1986 for treating respiratory syncytial virus (RSV) infection in children, currently one of its major clinical indications. Despite three decades of research, ribavirin's mechanism of action remained incompletely understood, though evidence accumulated supporting multiple mechanisms: direct incorporation into viral genomes leading to lethal mutagenesis, chain termination effects on viral polymerase, immune modulation through induction of interferon-stimulated genes (ISGs), and potentially additional effects on cellular antiviral responses.[25]

*Corresponding Author: **Oluwapelumi S. Ogunlusi**

The clinical limitations of ribavirin, however, became apparent during attempts to extend its use beyond RSV. In the early 1990s, ribavirin monotherapy showed limited efficacy against hepatitis C, achieving only modest effects on liver function tests. The breakthrough came in 1998 when combination therapy with interferon-alpha was found to produce synergistic effects, increasing sustained virological response rates from 6-15% (interferon monotherapy) to 36% with ribavirin combination therapy. Later, pegylated interferon combined with ribavirin achieved SVR rates of approximately 55%. While ribavirin proved valuable in combination therapy, its toxicity profile limited higher-dose use, and its broad-spectrum activity seemingly an advantage also meant nonspecific effects and potential toxicity to host cells.[26]

Early attempts to develop other broad-spectrum agents revealed fundamental challenges in the approach. Thiosemicarbazones, identified in 1950 during research into vaccinia virus (the first antiviral agents ever identified), showed some broad-spectrum activity but lacked selectivity and proved too toxic for clinical use. The gap between the theoretical appeal of broad-spectrum antivirals and their practical clinical utility during this era led to a shift in focus: rather than investing in difficult broad-spectrum development, the pharmaceutical industry increasingly concentrated on virus-specific agents, where structural knowledge and target validation were achievable, reducing development risk and enabling patent protection of novel compounds.[27]

2. Mechanisms of Action in Broad-Spectrum Antivirals

2.1 Direct-Acting Antivirals

2.1.1 Viral Entry Inhibitors

Membrane fusion represents an essential early step in enveloped virus infection, making it an attractive target for broad-spectrum intervention [28]. Viral fusion is mediated by conserved class I fusion proteins present on diverse enveloped viruses, including the influenza hemagglutinin and coronavirus spike proteins [29]. These proteins undergo large-scale conformational rearrangements, transitioning from a metastable prefusion state to a thermodynamically stable post-fusion configuration that drives membrane fusion [30]. Small-molecule inhibitors targeting conserved elements in this fusion transition have demonstrated broad-spectrum activity. Broad tricyclic ring inhibitors identified through experimental screening interact with conserved binding pockets on the spike proteins of SARS-CoV-1, SARS-CoV-2, and all SARS-CoV-2 variants tested, blocking conformational changes required for viral entry without necessarily preventing receptor binding [31]. These compounds define a highly conserved topography amenable to pan-coronavirus targeting [32].

Rigid Amphipathic Fusion Inhibitors (RAFIs) represent a distinct mechanistic approach, targeting the lipid membranes themselves rather than viral proteins [33]. RAFIs specifically inhibit the transition from positive to negative membrane curvature required for hemifusion, demonstrating activity against diverse unrelated enveloped viruses, including herpes simplex virus type-1, with selectivity indices of approximately 50 nM and minimal cytotoxicity. This membrane-targeting approach offers intrinsic broad-spectrum potential, as all enveloped viruses depend upon similar membrane fusion mechanisms regardless of their specific attachment proteins [34].

Pan-coronavirus fusion inhibitor lipopeptides based on the heptad repeat regions of coronavirus spike proteins achieve nanomolar-range potency against SARS-CoV-2 and SARS-CoV pseudoviruses [35]. Structure-activity relationship studies reveal that both N-terminal and C-terminal sequences, including the membrane-proximal external region, are critical for binding and antiviral capacity [36].

Clinical limitations of early peptide fusion inhibitors have been addressed through lipidation and conformational engineering. Lipopeptide-based fusion inhibitors exhibit substantially greater potency than their non-lipidated counterparts. Pan-coronavirus fusion inhibitor designs targeting conserved sequences across diverse coronavirus genera have shown activity against SARS-CoV, MERS-CoV, and endemic human coronaviruses [37].

2.1.2 Replication Complex Inhibitors

RNA-Dependent RNA Polymerase Inhibitors

The viral RNA-dependent RNA polymerase (RdRp) catalyzes RNA synthesis using nucleotide substrates and represents one of the most conserved viral enzymatic functions. Nucleoside and nucleotide analogues that inhibit RdRp exhibit broad-spectrum activity through two primary mechanisms: immediate chain termination or delayed chain termination. Remdesivir (GS-5734), a nucleotide analogue prodrug, demonstrates remarkable broad-spectrum activity against coronaviruses, filoviruses, and paramyxoviruses [38]. This kinetically reversible inhibition generates sustained antiviral pressure while minimizing some resistance mechanisms associated with immediate termination [39].

The structural basis of remdesivir inhibition involves selective steric incompatibility between the incorporated remdesivir monophosphate and the viral polymerase active site, combined with impaired base-pairing when remdesivir-containing templates are used in subsequent rounds of replication. This dual mechanism provides robustness against single-site resistance mutations [40].

Nucleoside Analogues and Metabolic Activation

Nucleoside analogues require metabolic activation through phosphorylation to their triphosphate forms before viral polymerase recognition. Most clinically relevant nucleoside analogues are administered as prodrugs with lipophilic substitutions that improve bioavailability [41]. This activation requirement introduces potential vulnerability: viruses with altered or enhanced excision activity can remove incorporated nucleoside analogues before productive chain termination. However, the reliance on ubiquitous cellular kinases rather than virus-specific activation machinery provides an inherent broad-spectrum advantage [42].

Protease Inhibitors with Pan-Viral Activity

Viral proteases catalyze polyprotein cleavage essential for maturation and replication. Although proteases exhibit greater sequence variability than polymerases, conserved catalytic mechanisms enable the development of pan-protease inhibitors. Novel papain-like protease (PLpro) inhibitors demonstrate broad-spectrum activity against alpha-, beta-, gamma-, and delta-coronaviruses [43]. Nirmatrelvir/ritonavir is one of the most effective antiviral drugs against SARS-CoV-2, with efficacy demonstrated through phase 2/3 clinical trials. Main protease (3CLpro) inhibitors exhibit submicromolar activity against multiple coronavirus species by targeting conserved active site geometry despite primary sequence variation [44]. Importantly, many viral proteases possess additional immune-regulatory functions through deubiquitination and NF-κB pathway modulation. Pan-protease inhibitors can therefore provide dual antiviral and immunomodulatory benefits [44].

2.1.3 Assembly and Release Inhibitors

Capsid Assembly Modulators

Capsid assembly represents a critical late-stage viral event potentially amenable to broad-spectrum targeting. Compounds that interfere with capsid protein quaternary assembly or RNA-protein interactions can prevent production of infectious progeny.

Viral Protein Transport Inhibitors

Nuclear export and intracellular trafficking of viral proteins represent essential processes targeted by host factors, including chromosomal region maintenance protein 1 (CRM1/XPO1). 4-Octyl itaconate (4-OI), an itaconate derivative and potential host-targeted antiviral, inhibits influenza A virus replication by restricting nuclear export of viral ribonucleoproteins. This mechanism provides potential broad-spectrum activity against other viruses dependent on CRM1-mediated export [45].

Neuraminidase Inhibitors

Neuraminidase, responsible for sialic acid cleavage and virion release, is shared across orthomyxoviruses and some paramyxoviruses. Neuraminidase inhibitors have achieved clinical success but face emerging resistance through mutations [46].

2.2 Host-Targeting Antivirals

2.2.1 Cellular Kinase Inhibitors

Cyclin-Dependent Kinase (CDK) Inhibitors

Cyclin-dependent kinases regulate both cell-cycle progression and RNA polymerase II-mediated transcription, processes exploited by diverse viruses for replication. CDK inhibitors demonstrate remarkably broad-spectrum antiviral activity across structurally unrelated virus families, including herpesviruses, papillomaviruses, polyomaviruses, adenoviruses, influenza viruses, and SARS-CoV-2. Mechanistically, CDK inhibition blocks immediate-early viral gene expression through effects on RNA polymerase II C-terminal domain phosphorylation [46]. CDK7 and CDK8 Inhibitors achieve picomolar-dose antiviral efficacy with cross-virus reactivity[41]. CDK7 inhibition directly and selectively blocks RNA polymerase II transcription initiation through effects on the transcription initiation complex. CDK8 inhibitors reduce viral replication even at nanomolar concentrations while showing broad-spectrum activity[46]. The advantage of CDK-targeting approaches in minimizing resistance emergence derives from the genetic stability of host CDKs[47].

Host Factor Modulation

Beyond kinases, multiple other host factors represent druggable targets. The ubiquitin-proteasome system (UPS) is exploited by coronaviruses for membrane fusion and uncoating. Cellular signaling pathways, including mTOR-PI3K-AKT, ABL-BCR/MAPK, and DNA damage response pathways, show antiviral activity when targeted[48].

2.2.2 Metabolic Pathway Modulators

Dihydroorotate Dehydrogenase (DHODH) Inhibitors

DHODH catalyzes the fourth enzymatic step in de novo pyrimidine synthesis, converting dihydroorotate to orotate. All RNA viruses fundamentally depend upon robust pyrimidine nucleotide pools for rapid RNA synthesis; accordingly, DHODH inhibition produces remarkably broad-spectrum antiviral activity[49]. Novel DHODH inhibitors (S312, S416) demonstrate nanomolar potency against diverse RNA viruses including influenza A virus (H1N1, H3N2, H9N2 subtypes), Zika virus, Ebola virus, and SARS-CoV-2. Notably, S416 achieves an EC50 of 17 nM against SARS-CoV-2-infected cells with a selectivity index >5882, among the most potent antivirals yet identified[49]. DHODH inhibition provides a particular advantage against nucleoside analogue-resistant viral strains[50]. In clinical trials, DHODH inhibitor activity against oseltamivir-resistant influenza strains exceeded oseltamivir by over 25-fold[50].

Inositol Metabolism Disruption

Inositol monophosphatase (IMPase) inhibition represents an emerging metabolic approach. Ivermectin, a broad-spectrum antiparasitic, exhibits antiviral activity through IMPase inhibition. Inhibitors targeting IMPase directly show broad-spectrum antiviral potential[51].

2.2.3 Immune System Modulators

Interferon Pathway Enhancement

Type I and type III interferons represent the innate immune system's first-line response to viral infection. Rather than providing interferon systemically, selective enhancement of endogenous interferon pathways through inhibition of negative regulators offers therapeutic promise. This approach provides genuinely broad-spectrum activity since the induced interferon-stimulated genes (ISGs) target conserved viral replication machinery [52].

In severe viral infections, excessive interferon and pro-inflammatory cytokine production contributes substantially to immunopathology. Host-directed antivirals simultaneously reducing viral replication and attenuating dysregulated immune responses offer particular advantage. DHODH inhibitors suppress pro-inflammatory gene expression through induction of regulatory T cells and inhibition of Th17 differentiation [53].

Similarly, p53 functions as a transcription factor, inducing antiviral effectors including p53-upregulated modulator of apoptosis (PUMA). CRM1 inhibition stabilizes p53 accumulation in nuclei through the prevention of nuclear export, thereby enhancing p53-dependent transcriptional responses [52].

3. Natural Products as Sources of Broad-Spectrum Antivirals

3.1 Plant-Derived Compounds

Traditional Medicine Approaches and Molecular Basis

Traditional medicine systems have preserved knowledge of antiviral plant preparations spanning centuries. Systematic investigation of these ethnopharmacological leads has identified active compounds and validated their mechanisms. Over 8000 characterized flavonoid compounds exist across plant species, with substantial antiviral activity demonstrated against coronaviruses, flaviviruses, orthomyxoviruses, and herpesviruses [54].

Flavonoids and Multi-Target Mechanisms

Flavonoids represent a privileged pharmacophore for broad-spectrum antiviral development. Quercetin demonstrates activity against multiple coronavirus genera through inhibition of the 3CL protease and modulation of spike protein-ACE2 interactions. Baicalein achieves potent dengue virus inhibition. Epigallocatechin gallate (EGCG) and other catechins inhibit diverse enveloped viruses. Crucially, flavonoid potency frequently increases dramatically when structurally distinct flavonoids are combined [55]. Mechanistically, flavonoids act through multiple pathways simultaneously: direct enzymatic inhibition of viral proteases and polymerases; membrane disruption; induction of ROS-mediated viral damage; and immune modulation through NF-κB and MAPK pathway effects. This multi-target approach inherently limits resistance emergence [56].

Challenges in Standardization and Optimization

Despite remarkable antiviral potential, plant-derived compounds face substantial development challenges. Standardization requires establishing consistent active compound levels and demonstrating that standardized fractions retain full antiviral spectrum of crude extracts. Chemical derivatization and rational structure-activity relationship studies can enhance potency and selectivity [57].

3.2 Marine Natural Products

Unique Structural Diversity for Antiviral Applications

Marine organisms produce bioactive compounds with structural scaffolds absent from terrestrial organisms. Marine sponges have yielded multiple lead compounds: nucleosides including spongosine and spongothymidine, represent early marine antiviral leads. Calyceramides from *Discodermia calyx* inhibit neuraminidase of influenza viruses [58]. Polyacetylenetriol compounds from marine sponges inhibit both DNA and RNA-directed polymerases. Thalassoilins from seagrass inhibit HIV reverse transcriptase and integrase [84]. Marine-derived polysaccharides and sulfated compounds obstruct viral entry [59]. High-throughput virtual screening using marine compound libraries represents an efficient approach to prioritize compounds for biological testing. Molecular docking studies evaluating marine compound libraries against conserved viral targets have identified promising candidates [60]. Sustainable approaches include cultivation of marine organisms in aquaculture systems, total chemical synthesis of promising scaffolds, or biological synthesis through engineered microorganisms.

3.3 Fungal Secondary Metabolites

Terpenoids with Broad-Spectrum Activity

Fungal secondary metabolites, particularly sesquiterpenes and triterpenes, demonstrate remarkable antiviral activity. Gossypol, a polyphenolic terpenoid, broadly inhibits coronaviruses by targeting the RNA-dependent RNA polymerase. Triterpenoid-mediated inhibition of virus-host interactions provides another dimension to fungal antiviral potential [61]. Genome mining approaches leverage fungal genomic sequences to predict biosynthetic gene clusters encoding secondary metabolites. CRISPR-based activation of silent biosynthetic pathways enables conditional expression of bioactive metabolites [62].

4. Technological Advances in Broad-Spectrum Antiviral Discovery

4.1 Artificial Intelligence and Machine Learning

4.1.1 Drug Discovery Platforms

Deep neural networks trained on curated datasets of peptide antiviral activity enable rapid classification of novel peptide sequences. Generative deep learning models enable de novo design of novel chemical structures predicted to possess desired antiviral properties. Reinforcement le/arning approaches can further optimize generated compounds for multiple objectives including oral bioavailability and metabolic stability. Recent successes using deep reinforcement learning identified novel compounds with demonstrated *in vitro* and *in vivo* antiviral activity [63,64]. Similarly, high-throughput virtual screening leverages structure-based drug design principles, using molecular docking to predict binding modes and affinities. Virtual screening has successfully identified FDA-approved drugs with unexpected antiviral activity, enabling rapid drug repurposing [65].

4.1.2 Target Identification and Validation

Machine learning approaches analyzing genome-wide association study data, RNA-seq expression datasets, and protein-protein interaction networks systematically identify host factors critical for viral replication. Integration of multi-omic datasets provides a comprehensive systems-level understanding of viral-host biology [66]. Cryo-electron microscopy combined with AI-assisted structure prediction enables rapid elucidation of viral-host complexes. Machine learning models trained on large viral sequencing databases predict which resistance mutations are most likely to emerge.

4.2 Computational Drug Design

X-ray crystallography and cryo-EM structures of viral proteins provide atomic-resolution templates for rational inhibitor design. Molecular dynamics simulations predict how small-molecule inhibitors perturb protein conformational

dynamics [67]. Quantitative structure-activity relationship (QSAR) modeling correlates molecular descriptors with antiviral activity. Pharmacophore models identify essential spatial arrangements of molecular features required for antiviral binding [68]. Computational prediction of absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties enables early elimination of compounds likely to fail clinical development. Machine learning models trained on extensive datasets from pharmaceutical development predict human hepatic clearance, renal excretion, and intrinsic hepatotoxicity [69].

5. Drug Resistance and Mitigation Strategies

5.1 Mechanisms of Antiviral Resistance

Viral nucleotide polymerases introduce mutations at rates of 10^{-3} to 10^{-5} errors per nucleotide incorporated, generating diverse viral quasispecies populations. Under antiviral selective pressure, rare pre-existing resistance mutations become enriched, or novel mutations emerge during active replication. SARS-CoV-2 main protease exhibits multiple naturally occurring resistance-conferring mutations [70]. Host-directed antivirals inherently present higher genetic barriers to resistance, as resistance requires viral adaptation to utilize alternative host cell factors. Mutations in host genes impose substantial selective pressure and typically reduce viral fitness more severely than mutations in viral genes [71]. Different viral families exhibit substantially different resistance development rates, reflecting differences in replication fidelity. RNA viruses typically exhibit higher mutation rates than DNA viruses.

5.2 Combination Therapy Approaches

Combination therapy employing agents with distinct mechanisms of action enhances viral suppression through additive or synergistic effects. The foundational principle holds that simultaneous acquisition of resistance to multiple non-cross-resistant drugs requires sequential independent mutations. HIV highly active antiretroviral therapy (HAART) exemplifies this approach. For COVID-19, remdesivir combined with baricitinib demonstrated synergistic improvement in clinical outcomes [72].

Combining nucleoside analogues with metabolic pathway inhibitors can enhance polymerase inhibitor efficacy. Depleted nucleotide pools increase the fraction of polymerase active sites that encounter nucleoside analogue substrates [73]. Sophisticated combination designs targeting multiple steps in viral life cycles create multiple independent barriers to viral escape [74].

5.3 Resistance Surveillance and Monitoring

Next-generation sequencing enables rapid detection of resistance-conferring mutations in viral populations. Digital droplet PCR and ultra-sensitive techniques detect specific resistance mutations at frequencies below conventional Sanger sequencing detection limits [75]. Antiviral resistance emergence has substantial clinical implications ranging from treatment failure to severe disease. Immunocompromised patients experience higher resistance emergence rates. Rotating antiviral agents reduces the accumulation of multiple resistance mutations. Optimizing dosing regimens maintains drug concentrations above resistance-emergence thresholds [75].

6. Clinical Development and Translation

6.1 Preclinical Evaluation Models

Standardized cell culture infection models using panels of representative viruses enable quantitative assessment of broad-spectrum antiviral activity. Primary human cells more accurately reflect *in vivo* antiviral efficacy than immortalized cell lines. Dose-response curves characterize potency (IC50, EC50) and selectivity indices [76]. Validated animal models of viral infection provide essential *in vivo* efficacy data. Transgenic mice expressing human viral receptors develop severe pneumonia comparable to severe human disease. Ferret models better recapitulate human respiratory virus pathophysiology. Non-human primate models closely mirror human disease but require substantial ethical justification [77]. Identification and validation of biomarkers predicting antiviral response guides dose selection. Viral load kinetics, inflammatory marker reductions, and immune activation markers correlate with clinical outcomes. Pharmacogenomic biomarkers predict individual antiviral efficacy variability [77].

6.2 Current Clinical Pipeline

Contemporary broad-spectrum antiviral development includes diverse mechanistic classes: next-generation nucleoside analogues (molnupiravir, remdesivir, favipiravir); protease inhibitors (nirmatrelvir/ritonavir); host-directed antivirals (DHODH inhibitors, CDK inhibitors); and immunomodulators [78]. High-throughput screening of existing pharmaceutical libraries has identified multiple FDA-approved drugs with unexpected antiviral activity. Remdesivir and molnupiravir exemplify successful drug repurposing [79]. Emergency Use Authorizations enable deployment of agents with promising preliminary efficacy data. These pathways require post-authorization surveillance and commitment to complete conventional trials [79].

7. Specific Applications and Case Studies

7.1 Respiratory Virus Pandemics

The COVID-19 pandemic provided unprecedented opportunities to evaluate broad-spectrum antiviral concepts. Early pandemic development of remdesivir, monoclonal antibodies, and later protease inhibitors demonstrated that rapid drug development and deployment was feasible. However, critical limitations emerged: monoclonal antibody therapeutics proved vulnerable to viral escape through spike protein mutations [80]. Influenza represents a perennial challenge requiring annual vaccine updates. While seasonal influenza vaccines typically prevent 40-60% of infections, the emergence of pandemic strains with pandemic potential necessitates pandemic preparedness, including antivirals. DHODH inhibitors demonstrate remarkable potency against

influenza, including oseltamivir-resistant strains [81]. Additional respiratory pathogens beyond SARS-CoV-2 and seasonal influenza pose pandemic potential. Nipah virus, Hendra virus, and MERS-CoV represent a high-priority biosafety threat. Pre-development of broad-spectrum antivirals against these agents would substantially improve pandemic preparedness [82]

7.2 Hemorrhagic Fever Viruses

Ebola and Marburg Virus Therapeutics

Filoviruses cause hemorrhagic fever with fatality rates exceeding 50%. Remdesivir demonstrated a 60% mortality reduction in hospitalized patients during the 2018-2020 Ebola outbreak. Subsequently approved monoclonal antibody therapeutics provide additional options [83,84]. Host-directed antivirals targeting filovirus-essential cellular processes offer promise. Identification of cellular factors exploited by multiple filovirus genera enables the development of single agents effective across diverse filoviruses [84]. Filovirus research involves biosafety level 4 pathogens requiring specialized infrastructure. Clinical trials during active outbreaks occur under extreme circumstances [84].

8. Challenges and Limitations

8.1 Scientific and Technical Challenges

Achieving both broad-spectrum activity and high potency presents fundamental challenges. Compounds targeting highly conserved viral targets frequently lack potency against individual viruses. Optimization requires iterative structure-activity relationship studies [85]. Broad-spectrum compounds frequently demonstrate cellular toxicity at antiviral concentrations. Enhancement of selectivity indices through medicinal chemistry modifications faces the challenge that improvements in selectivity often reduce antiviral potency [85]. Many promising broad-spectrum antivirals suffer from poor aqueous solubility, rapid hepatic metabolism, or limited cellular penetration. Nanotechnology-based delivery systems can substantially improve bioavailability. However, nanoparticle formulations introduce manufacturing complexity [86].

8.2 Regulatory and Economic Barriers

Prophylactic antiviral use faces higher regulatory scrutiny regarding safety. Regulatory frameworks historically emphasize symptom resolution as justification for therapeutic risk acceptance. Prophylactic use requires demonstrating that prevented infections justify any potential adverse effects [87]. Economic considerations substantially influence broad-spectrum antiviral development. Virus-specific antivirals enable market segmentation and price discrimination. These market dynamics reduce economic incentives for broad-spectrum development despite superior public health benefits [88].

9. Future Directions and Emerging Opportunities

9.1 Next-Generation Technologies

Nanoparticle-based drug delivery systems dramatically improve antiviral bioavailability through enhanced solubility, cellular penetration, and sustained release. Ligand-targeted nanoparticles specifically deliver antivirals to infected tissues. Polymeric nanoparticles, liposomes, lipid nanoparticles (LNPs), and hybrid systems each offer distinct advantages [89]. Nanoparticle platforms themselves frequently exhibit direct antiviral activity independent of loaded medications. Integration of multiple antivirals with complementary mechanisms into single nanoparticles could enable delivery of combination therapy through simplified dosing regimens [89]. CRISPR-Cas systems offer direct targeting of conserved viral genome sequences using Cas nucleases. Host gene targeting provides particular advantages for broad-spectrum activity. CRISPR delivery to systemic viral infections requires overcoming substantial challenges. Localized delivery represents nearer-term feasible applications [90].

9.2 Precision Medicine Applications

Genetic variation in antiviral metabolism substantially influences individual antiviral efficacy and tolerability. Incorporating pharmacogenomic testing into antiviral deployment enables dose optimization. Population-specific pharmacogenomic profiles ensure equitable optimization across diverse populations [91]. Assessment of individual host factor expression levels could enable the selection of antivirals optimally targeting an individual's specific host factor status. Patients with robust innate immune responses might preferentially benefit from immunomodulatory broad-spectrum agents [92]. Continuous surveillance of treated patients' viral populations using high-sensitivity sequencing enables rapid detection of emerging resistance mutations. Machine learning models integrating resistance mutation detection with clinical outcomes data could enable real-time therapeutic adjustments [93].

Conclusions and Recommendations

Broad-spectrum antiviral development has transitioned from a theoretical concept to a clinical reality. Direct-acting antivirals targeting conserved viral replication machinery demonstrate substantial broad-spectrum potential. Host-directed antivirals provide complementary approaches with a potentially superior resistance barrier. Natural products demonstrate broad-spectrum activity and represent underexploited sources. Integration of AI, machine learning, and computational chemistry has accelerated compound discovery substantially. Despite progress, substantial gaps remain, including: clinical trial designs inadequately prepared for rapid pandemic deployment; insufficient government funding for development of therapeutics addressing non-pandemic viruses; limited global manufacturing capacity for surge production; inadequate diagnostic infrastructure; and persistent inequities in antiviral access.

Governments should prioritize policies that enable rapid, broad-spectrum antiviral development through: dedicated funding mechanisms separate from traditional research grant systems; regulatory frameworks that enable adaptive clinical trial designs; intellectual property protections that incentivize broad-spectrum development; investments in stockpiling

*Corresponding Author: **Oluwapelumi S. Ogunlusi**

infrastructure and surge manufacturing capacity; and international collaboration frameworks.

REFERENCES

1. Zhang, J., Hu, Y., Foley, C., Wang, Y., Musharrafieh, R., Xu, S., Zhang, Y., Ma, C., Hulme, C., & Wang, J. (2018). Exploring Ugi-Azide Four-Component Reaction Products for Broad-Spectrum Influenza Antivirals with a High Genetic Barrier to Drug Resistance. Scientific Reports, 8(1). https://doi.org/10.1038/s41598-018-22875-9
2. Karim, M., Lo, C., & Einav, S. (2023). Preparing for the next viral threat with broad-spectrum antivirals. Journal of Clinical Investigation, 133(11). https://doi.org/10.1172/jci170236
3. SPRIND |. (n.d.). Bundesagentur Für Sprunginnovationen. https://www.sprind.org/en/words/magazine/broad-spectrum-antivirals-blog-post
4. Martin, D. E., & Tripp, R. A. (2024). Host-directed antiviral therapeutics and the NIAID research agenda: an underexplored frontier. Frontiers in Virology, 4. https://doi.org/10.3389/fviro.2024.1458112
5. Li, G., Hilgenfeld, R., Whitley, R., & De Clercq, E. (2023). Therapeutic strategies for COVID-19: progress and lessons learned. Nature Reviews Drug Discovery, 22(6), 449–475. https://doi.org/10.1038/s41573-023-00672-y
6. Chitalia, V. C., & Munawar, A. H. (2020). A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antivirals. Journal of Translational Medicine, 18(1). https://doi.org/10.1186/s12967-020-02476-9
7. Singh, N., Vayer, P., Tanwar, S., Poyet, J., Tsaioun, K., & Villoutreix, B. O. (2023). Drug discovery and development: introduction to the general public and patient groups. Frontiers in Drug Discovery, 3. https://doi.org/10.3389/fddsv.2023.1201419
8. Government of the U.K. (2024, August 15). Broad-spectrum antivirals. https://www.gov.uk/government/publications/broad-spectrum-antivirals/broad-spectrum-antivirals
9. Robinson, P. C., Liew, D. F. L., Tanner, H. L., Grainger, J. R., Dwek, R. A., Reisler, R. B., Steinman, L., Feldmann, M., Ho, L., Hussell, T., Moss, P., Richards, D., & Zitzmann, N. (2022). COVID-19 therapeutics: Challenges and directions for the future. Proceedings of the National Academy of Sciences, 119(15). https://doi.org/10.1073/pnas.2119893119
10. Anish, T. S., Aravind, R., Radhakrishnan, C., Gupta, N., Yadav, P. D., Cherian, J. J., Sahay, R., Chenayil, S., S, A. K. A., Moorkoth, A. P., Ashadevi, N., Lathika, V. R., Moideen, S., Kuriakose, S. L., Reena, K. J., & Mathew, T. (2024). Pandemic potential of the Nipah virus and public health strategies adopted during outbreaks: Lessons from Kerala, India. PLOS Global Public Health, 4(12), e0003926. https://doi.org/10.1371/journal.pgph.0003926
11. Wikipedia contributors. (2025, September 3). Antiviral drug. Wikipedia. https://en.wikipedia.org/wiki/Antiviral_drug
12. Eastman, R. T., Roth, J. S., Brimacombe, K. R., Simeonov, A., Shen, M., Patnaik, S., & Hall, M. D. (2020). Remdesivir: A review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS Central Science, 6(5), 672–683. https://doi.org/10.1021/acscentsci.0c00489
13. Xie, X., Lan, Q., Zhao, J., Zhang, S., Liu, L., Zhang, Y., Xu, W., Shao, M., Peng, J., Xia, S., Zhu, Y., Zhang, K., Zhang, X., Zhang, R., Li, J., Dai, W., Ge, Z., Hu, S., Yu, C., . . . Liu, H. (2024). Structure-based design of pan-coronavirus inhibitors targeting host cathepsin L and calpain-1. Signal Transduction and Targeted Therapy, 9(1). https://doi.org/10.1038/s41392-024-01758-8
14. Fang, H., Wang, Y., Liu, L., Cheng, K., Li, P., Tan, Y., Hao, X., Mei, M., Xu, X., Yao, Y., Zan, F., Wu, L., Zhu, Y., Xu, B., Huang, D., Wang, C., Tan, X., Qian, Z., & Chen, X. (2022). A Host-Harbored metabolic susceptibility of coronavirus enables Broad-Spectrum targeting. bioRxiv (Cold Spring Harbor Laboratory). https://doi.org/10.1101/2022.12.07.519404
15. https://www.gov.uk/government/publications/broad-spectrum-antivirals/broad-spectrum-antivirals
16. Geraghty, R., Aliota, M., & Bonnac, L. (2021). Broad-Spectrum antiviral strategies and nucleoside analogues. Viruses, 13(4), 667. https://doi.org/10.3390/v13040667
17. Zhu, Y., Gao, Z., Feng, X., Cheng, L., Liu, N., Liu, C., Han, S., Yang, Q., Zou, Q., Chong, H., Zhang, Z., Li, M., Song, G., & He, Y. (2024). Development of potent pan-coronavirus fusion inhibitors with a new design strategy. MedComm, 5(8). https://doi.org/10.1002/mco2.6666
18. Guo, L., Lin, S., Chen, Z., Cao, Y., He, B., & Lu, G. (2023). Targetable elements in SARS-CoV-2 S2 subunit for the design of pan-coronavirus fusion inhibitors and vaccines. Signal Transduction and Targeted Therapy, 8(1). https://doi.org/10.1038/s41392-023-01472-x
19. Progress toward a broad-spectrum antiviral. (2025, September 18). National Institutes of Health (NIH). https://www.nih.gov/news-events/nih-research-matters/progress-toward-broad-spectrum-antiviral
20. https://www.gavi.org/vaccineswork/scientists-make-breakthrough-towards-universal-antiviral-drugs
21. Korsman, S. N., Van Zyl, G. U., Nutt, L., Andersson, M. I., & Preiser, W. (2012). Antiviral drugs–. In Elsevier eBooks (pp. 36–41).

https://doi.org/10.1016/b978-0-443-07367-0.00018-5

22. Sohn, S., Hearing, J., Mugavero, J., Kirillov, V., Gorbunova, E., Helminiak, L., Mishra, S., Mackow, E., Hearing, P., Reich, N. C., & Kim, H. K. (2021). Interferon-Lambda intranasal protection and differential sex pathology in a murine model of SARS-COV-2 infection. mBio, 12(6). https://doi.org/10.1128/mbio.02756-21
23. Dijkman, R., Verma, A. K., Selvaraj, M., Ghimire, R., Gad, H. H., Hartmann, R., More, S., Perlman, S., Thiel, V., & Channappanavar, R. (2022). Effective interferon lambda treatment regimen to control lethal MERS-COV infection in mice. Journal of Virology, 96(11). https://doi.org/10.1128/jvi.00364-22
24. Thomas, E., Ghany, M. G., & Liang, T. J. (2012). The application and mechanism of action of Ribavirin in therapy of hepatitis C. Antiviral Chemistry & Chemotherapy, 23(1), 1–12. https://doi.org/10.3851/imp2125
25. Westover, J. B., Sefing, E. J., Bailey, K. W., Van Wettere, A. J., Jung, K., Dagley, A., Wandersee, L., Downs, B., Smee, D. F., Furuta, Y., Bray, M., & Gowen, B. B. (2015). Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses. Antiviral Research, 126, 62–68. https://doi.org/10.1016/j.antiviral.2015.12.006
26. Wu, J. Z. (2003). Ribavirin, viramidine and adenosine-deaminase-catalysed drug activation: implication for nucleoside prodrug design. Journal of Antimicrobial Chemotherapy, 52(4), 543–546. https://doi.org/10.1093/jac/dkg405
27. De Clercq, E. (2010). Historical perspectives in the development of antiviral agents against poxviruses. Viruses, 2(6), 1322–1339. https://doi.org/10.3390/v2061322
28. Fu, L., Ye, F., Feng, Y., Yu, F., Wang, Q., Wu, Y., Zhao, C., Sun, H., Huang, B., Niu, P., Song, H., Shi, Y., Li, X., Tan, W., Qi, J., & Gao, G. F. (2020). Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. Nature Communications, 11(1), 4417. https://doi.org/10.1038/s41467-020-18233-x
29. Kokic, G., Hillen, H. S., Tegunov, D., Dienemann, C., Seitz, F., Schmitzova, J., Farnung, L., Siewert, A., Höbartner, C., Cramer, P., Kokic, G., Hillen, H. S., Tegunov, D., Dienemann, C., Seitz, F., Schmitzova, J., Farnung, L., Siewert, A., Höbartner, C., & Cramer, P. (2021). Mechanism of SARS-CoV-2 polymerase stalling by remdesivir. Nature Communications, 12(1). https://doi.org/10.1038/s41467-020-20542-0
30. Gordon CJ, Tchesnokov EP, Feng JY, et al. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem. 2020;295(15):4773-4779.
31. Ratnapriya, S., Braun, A. R., Benet, H. C., Carlson, D., Ding, S., Paulson, C. N., Mishra, N., Sachs, J. N., Aldrich, C. C., Finzi, A., & Herschhorn, A. (2022). Broad tricyclic ring inhibitors block SARS-COV-2 spike function required for viral entry. ACS Infectious Diseases, 8(10), 2045–2058. https://doi.org/10.1021/acsinfecdis.1c00658
32. Zhu, Y., Yu, D., Yan, H., Chong, H., & He, Y. (2020). Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity. Journal of Virology, 94(14). https://doi.org/10.1128/jvi.00635-20
33. Hakobyan A, Galindo I, Nañez A, Arabyan E, Karalyan Z, Chistov AA, Streshnev PP, Korshun VA, Alonso C, Zakaryan H. Rigid amphipathic fusion inhibitors demonstrate antiviral activity against African swine fever virus. J Gen Virol. 2018 Jan;99(1):148-156. doi: 10.1099/jgv.0.000991. Epub 2017 Dec 13. PMID: 29235978.
34. Yao H, Song Y, Chen Y, Wu N, Xu J, Sun C, Zhang J, Weng T, Zhang Z, Wu Z, Cheng L, Shi D, Lu X, Lei J, Crispin M, Shi Y, Li L, Li S. Molecular Architecture of the SARS-CoV-2 Virus. Cell. 2020 Oct 29;183(3):730-738.e13. doi: 10.1016/j.cell.2020.09.018. Epub 2020 Sep 6. PMID: 32979942; PMCID: PMC7474903.
35. Xia, S., Liu, M., Wang, C., Xu, W., Lan, Q., Feng, S., Qi, F., Bao, L., Du, L., Liu, S., Qin, C., Sun, F., Shi, Z., Zhu, Y., Jiang, S., & Lu, L. (2020). Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Research, 30(4), 343–355. https://doi.org/10.1038/s41422-020-0305-x
36. Zhu, Y., Gao, Z., Feng, X., Cheng, L., Liu, N., Liu, C., Han, S., Yang, Q., Zou, Q., Chong, H., Zhang, Z., Li, M., Song, G., & He, Y. (2024). Development of potent pan-coronavirus fusion inhibitors with a new design strategy. *MedComm*, *5*(8), e666. https://doi.org/10.1002/mco2.666
37. Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, Lu G, Qiao C, Hu Y, Yuen KY, Wang Q, Zhou H, Yan J, Qi J. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. Cell. 2020 May 14;181(4):894-904.e9. doi: 10.1016/j.cell.2020.03.045. Epub 2020 Apr 9. PMID: 32275855; PMCID: PMC7144619.
38. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4. PMID: 32020029; PMCID: PMC7054408.

39. Bravo JPK, Dangerfield TL, Taylor DW, Johnson KA. Remdesivir is a delayed translocation inhibitor of SARS-CoV-2 replication. Mol Cell. 2021 Apr 1;81(7):1548-1552.e4. doi: 10.1016/j.molcel.2021.01.035. Epub 2021 Jan 28. PMID: 33631104; PMCID: PMC7843106.
40. Sheahan TP, Sims AC, Zhou S, Graham RL, Pruijssers AJ, Agostini ML, Leist SR, Schäfer A, Dinnon KH 3rd, Stevens LJ, Chappell JD, Lu X, Hughes TM, George AS, Hill CS, Montgomery SA, Brown AJ, Bluemling GR, Natchus MG, Saindane M, Kolykhalov AA, Painter G, Harcourt J, Tamin A, Thornburg NJ, Swanstrom R, Denison MR, Baric RS. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020 Apr 29;12(541):eabb5883. doi: 10.1126/scitranslmed.abb5883. Epub 2020 Apr 6. PMID: 32253226; PMCID: PMC7164393.
41. Eyer, L., Nencka, R., De Clercq, E., Seley-Radtke, K., & Růžek, D. (2018). Nucleoside analogs as a rich source of antiviral agents active against arthropod-borne flaviviruses. Antiviral Chemistry & Chemotherapy, 26, 2040206618761299. https://doi.org/10.1177/2040206618761299
42. Mahajan S, Choudhary S, Kumar P, Tomar S. Antiviral strategies targeting host factors and mechanisms obliging +ssRNA viral pathogens. Bioorg Med Chem. 2021 Sep 15;46:116356. doi: 10.1016/j.bmc.2021.116356. Epub 2021 Aug 8. PMID: 34416512; PMCID: PMC8349405.
43. Alvarez, N., Adam, G. C., Howe, J. A., Sharma, V., Zimmerman, M. D., Dolgov, E., Rasheed, R., Nizar, F., Sahay, K., Nelson, A. M., Park, S., Zhou, X., Burlein, C., Fay, J. F., Iwamoto, D. V., Bahnck-Teets, C. M., Getty, K. L., Goh, S. L., Salhab, I., . . . Perlin, D. S. (2024). Novel Pan-Coronavirus 3CL Protease Inhibitor MK-7845: Biological and Pharmacological Profiling. Viruses, 16(7), 1158. https://doi.org/10.3390/v16071158
44. Barkan, D. T., Garland, K., Zhang, L., Eastman, R. T., Hesse, M., Knapp, M., Ornelas, E., Tang, J., Cortopassi, W. A., Wang, Y., King, F., Jia, W., Nguyen, Z., Frank, A. O., Chan, R., Fang, E., Fuller, D., Busby, S., Carias, H., . . . Marx, V. M. (2024). Identification of potent, Broad-Spectrum coronavirus main protease inhibitors for pandemic preparedness. Journal of Medicinal Chemistry, 67(19), 17454–17471. https://doi.org/10.1021/acs.jmedchem.4c01404
45. Ribó-Molina, P., Weiss, H. J., Susma, B., Van Nieuwkoop, S., Persoons, L., Zheng, Y., Ruzek, M., Daelemans, D., Fouchier, R. a. M., O'Neill, L. a. J., & Van Den Hoogen, B. G. (2023). 4-Octyl itaconate reduces influenza A replication by targeting the nuclear export protein CRM1. Journal of Virology, 97(10), e0132523. https://doi.org/10.1128/jvi.01325-23
46. Hay AJ, Wolstenholme AJ, Skehel JJ, Smith MH. The molecular basis of the specific anti-influenza action of amantadine. EMBO J. 1985 Nov;4(11):3021-4. doi: 10.1002/j.1460-2075.1985.tb04038.x. PMID: 4065098; PMCID: PMC554613.
47. Yu D, Wagner S, Schütz M, Jeon Y, Seo M, Kim J, Brückner N, Kicuntod J, Tillmanns J, Wangen C, Hahn F, Kaufer BB, Neipel F, Eickhoff J, Klebl B, Nam K, Marschall M. An Antiherpesviral Host-Directed Strategy Based on CDK7 Covalently Binding Drugs: Target-Selective, Picomolar-Dose, Cross-Virus Reactivity. Pharmaceutics. 2024 Jan 23;16(2):158. doi: 10.3390/pharmaceutics16020158. PMID: 38399219; PMCID: PMC10892818.
48. Jiang L, Yu Y, Li Z, Gao Y, Zhang H, Zhang M, Cao W, Peng Q, Chen X. BMS-265246, a Cyclin-Dependent Kinase Inhibitor, Inhibits the Infection of Herpes Simplex Virus Type 1. Viruses. 2023 Jul 28;15(8):1642. doi: 10.3390/v15081642. PMID: 37631985; PMCID: PMC10459710.
49. Yuan X, Zhang X, Wang H, Mao X, Sun Y, Tan L, Song C, Qiu X, Ding C, Liao Y. The Ubiquitin-Proteasome System Facilitates Membrane Fusion and Uncoating during Coronavirus Entry. Viruses. 2023 Sep 26;15(10):2001. doi: 10.3390/v15102001. PMID: 37896778; PMCID: PMC10610886.
50. Xiong, R., Zhang, L., Li, S., Sun, Y., Ding, M., Wang, Y., Zhao, Y., Wu, Y., Shang, W., Jiang, X., Shan, J., Shen, Z., Tong, Y., Xu, L., Yu, C., Liu, Y., Zou, G., Lavillete, D., Zhao, Z., . . . Xu, K. (2020). Novel and potent inhibitors targeting DHODH, a rate-limiting enzyme inde novopyrimidine biosynthesis, are broad-spectrum antiviral against RNA viruses including newly emerged coronavirus SARS-CoV-2. *bioRxiv (Cold Spring Harbor Laboratory)*. https://doi.org/10.1101/2020.03.11.983056
51. Purificação, A. D., Silva-Mendonça, S., Cruz, L. V., Sacramento, C. Q., Temerozo, J. R., Fintelman-Rodrigues, N., De Freitas, C. S., Godoi, B. F., Vaidergorn, M. M., Leite, J. A., Alvarez, L. C. S., Freitas, M. V., Silvac, M. F. B., Martin, B. A., Lopez, R. F. V., Neves, B. J., Costa, F. T. M., Souza, T. M. L., Da Silva Emery, F., . . . Nonato, M. C. (2024). Unveiling the Antiviral Capabilities of Targeting Human Dihydroorotate Dehydrogenase against SARS-CoV-2. ACS Omega, 9(10), 11418–11430. https://doi.org/10.1021/acsomega.3c07845
52. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020 Jun;178:104787. doi: 10.1016/j.antiviral.2020.104787. Epub 2020 Apr 3. PMID: 32251768; PMCID: PMC7129059.

53. Haller O, Kochs G, Weber F. The interferon response circuit: induction and suppression by pathogenic viruses. Virology. 2006 Jan 5;344(1):119-30. doi: 10.1016/j.virol.2005.09.024. PMID: 16364743; PMCID: PMC7125643.
54. Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Møller R, Jordan TX, Oishi K, Panis M, Sachs D, Wang TT, Schwartz RE, Lim JK, Albrecht RA, tenOever BR. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell. 2020 May 28;181(5):1036-1045.e9. doi: 10.1016/j.cell.2020.04.026. Epub 2020 May 15. PMID: 32416070; PMCID: PMC7227586.
55. Newman DJ, Cragg GM. Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019. J Nat Prod. 2020 Mar 27;83(3):770-803. doi: 10.1021/acs.jnatprod.9b01285. Epub 2020 Mar 12. PMID: 32162523.
56. Agrawal PK, Agrawal C, Blunden G. Quercetin: Antiviral Significance and Possible COVID-19 Integrative Considerations. *Natural Product Communications*. 2020;15(12). doi:10.1177/1934578X20976293
57. Ninfali P, Antonelli A, Magnani M, Scarpa ES. Antiviral Properties of Flavonoids and Delivery Strategies. Nutrients. 2020; 12(9):2534. https://doi.org/10.3390/nu12092534
58. Fabricant DS, Farnsworth NR. The value of plants used in traditional medicine for drug discovery. Environ Health Perspect. 2001 Mar;109 Suppl 1(Suppl 1):69-75. doi: 10.1289/ehp.01109s169. PMID: 11250806; PMCID: PMC1240543.
59. Koehn FE, Carter GT. The evolving role of natural products in drug discovery. Nat Rev Drug Discov. 2005 Mar;4(3):206-20. doi: 10.1038/nrd1657. PMID: 15729362.
60. Skropeta, D., & Wei, L. (2014). Recent advances in deep-sea natural products. Natural Product Reports, 31(8), 999–1025. https://doi.org/10.1039/c3np70118b
61. Asiamah, I., Obiri, S. A., Tamekloe, W., Armah, F. A., & Borquaye, L. S. (2023). Applications of molecular docking in natural products-based drug discovery. Scientific African, 20, e01593. https://doi.org/10.1016/j.sciaf.2023.e01593
62. Wang W, Li W, Wen Z, Wang C, Liu W, Zhang Y, Liu J, Ding T, Shuai L, Zhong G, Bu Z, Qu L, Ren M, Li F. Gossypol Broadly Inhibits Coronaviruses by Targeting RNA-Dependent RNA Polymerases. Adv Sci (Weinh). 2022 Dec;9(35):e2203499. doi: 10.1002/advs.202203499. Epub 2022 Oct 20. PMID: 36266926; PMCID: PMC9762316.
63. Albarano, L., Esposito, R., Ruocco, N., & Costantini, M. (2020). Genome mining as new challenge in natural products discovery. Marine Drugs, 18(4), 199. https://doi.org/10.3390/md18040199
64. Gangwal, A., Ansari, A., Ahmad, I., Azad, A. K., Kumarasamy, V., Subramaniyan, V., & Wong, L. S. (2024). Generative artificial intelligence in drug discovery: basic framework, recent advances, challenges, and opportunities. Frontiers in Pharmacology, 15, 1331062. https://doi.org/10.3389/fphar.2024.1331062
65. Ferreira, F. J. N., & Carneiro, A. S. (2025). AI-Driven Drug Discovery: A Comprehensive Review. ACS Omega, 10(23), 23889–23903. https://doi.org/10.1021/acsomega.5c00549
66. Shoichet BK. Virtual screening of chemical libraries. Nature. 2004 Dec 16;432(7019):862-5. doi: 10.1038/nature03197. PMID: 15602552; PMCID: PMC1360234.
67. Chen G, Jiang J, Sun Y. RNAVirHost: a machine learning-based method for predicting hosts of RNA viruses through viral genomes. Gigascience. 2024 Jan 2;13:giae059. doi: 10.1093/gigascience/giae059. PMID: 39172545; PMCID: PMC11340644.
68. Leach, A. R., Shoichet, B. K., & Peishoff, C. E. (2006). Prediction of Protein−Ligand Interactions. Docking and Scoring: Successes and Gaps. Journal of Medicinal Chemistry, 49(20), 5851–5855. https://doi.org/10.1021/jm060999m
69. Dudley JT, Butte AJ. Identification of discriminating biomarkers for human disease using integrative network biology. Pac Symp Biocomput. 2009:27-38. PMID: 19209693; PMCID: PMC2749008.
70. Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov. 2007 Nov;6(11):881-90. doi: 10.1038/nrd2445. PMID: 17971784.
71. Kumar S, Thambiraja TS, Karuppanan K, Subramaniam G. Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein. J Med Virol. 2022 Apr;94(4):1641-1649. doi: 10.1002/jmv.27526. Epub 2021 Dec 27. PMID: 34914115.
72. Kumar N, Sharma S, Kumar R, Meena VK, Barua S. Evolution of drug resistance against antiviral agents that target cellular factors. Virology. 2024 Dec;600:110239. doi: 10.1016/j.virol.2024.110239. Epub 2024 Sep 13. PMID: 39276671.
73. Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, Marconi VC, Ruiz-Palacios GM, Hsieh L, Kline S, Tapson V, Iovine NM, Jain MK, Sweeney DA, El Sahly HM, Branche AR, Regalado Pineda J, Lye DC, Sandkovsky U, Luetkemeyer AF, Cohen SH, Finberg RW, Jackson PEH, Taiwo B, Paules CI, Arguinchona H, Erdmann N, Ahuja N, Frank M, Oh MD, Kim ES, Tan SY, Mularski RA, Nielsen H, Ponce PO, Taylor BS, Larson L, Rouphael NG, Saklawi Y, Cantos

VD, Ko ER, Engemann JJ, Amin AN, Watanabe M, Billings J, Elie MC, Davey RT, Burgess TH, Ferreira J, Green M, Makowski M, Cardoso A, de Bono S, Bonnett T, Proschan M, Deye GA, Dempsey W, Nayak SU, Dodd LE, Beigel JH; ACTT-2 Study Group Members. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2021 Mar 4;384(9):795-807. doi: 10.1056/NEJMoa2031994. Epub 2020 Dec 11. PMID: 33306283; PMCID: PMC7745180.

74. Asin-Milan O, Sylla M, El-Far M, Belanger-Jasmin G, Haidara A, Blackburn J, Chamberland A, Tremblay CL. Synergistic combinations of the CCR5 inhibitor VCH-286 with other classes of HIV-1 inhibitors. Antimicrob Agents Chemother. 2014 Dec;58(12):7565-9. doi: 10.1128/AAC.03630-14. Epub 2014 Sep 29. PMID: 25267674; PMCID: PMC4249518.
75. Gottlieb RL, Nirula A, Chen P, Boscia J, Heller B, Morris J, Huhn G, Cardona J, Mocherla B, Stosor V, Shawa I, Kumar P, Adams AC, Van Naarden J, Custer KL, Durante M, Oakley G, Schade AE, Holzer TR, Ebert PJ, Higgs RE, Kallewaard NL, Sabo J, Patel DR, Klekotka P, Shen L, Skovronsky DM. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2021 Feb 16;325(7):632-644. doi: 10.1001/jama.2021.0202. PMID: 33475701; PMCID: PMC7821080.
76. Schadron T, van den Beld M, Mughini-Gras L, Franz E. Use of whole genome sequencing for surveillance and control of foodborne diseases: *status quo* and *quo vadis*. Front Microbiol. 2024 Sep 13;15:1460335. doi: 10.3389/fmicb.2024.1460335. PMID: 39345263; PMCID: PMC11427404.
77. Zhang C, Feng Y, Wong G, Wang L, Cechetto J, Blanchard J, Brown E, Mahony J. Development of a Cell-Based Assay for Identification of Viral Entry Inhibitors Against SARS-CoV by High Throughput Screening (HTS). Antiviral Res. 2007 Jun;74(3):A82. doi: 10.1016/j.antiviral.2007.01.143. Epub 2007 Feb 22. PMCID: PMC7133825.
78. Leist SR, Dinnon KH 3rd, Schäfer A, Tse LV, Okuda K, Hou YJ, West A, Edwards CE, Sanders W, Fritch EJ, Gully KL, Scobey T, Brown AJ, Sheahan TP, Moorman NJ, Boucher RC, Gralinski LE, Montgomery SA, Baric RS. A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice. Cell. 2020 Nov 12;183(4):1070-1085.e12. doi: 10.1016/j.cell.2020.09.050. Epub 2020 Sep 23. PMID: 33031744; PMCID: PMC7510428.
79. Hoang PT, Luong QXT, Ayun RQ, Lee Y, Vo TTB, Kim T, Lee S. A Novel Approach of Antiviral Drugs Targeting Viral Genomes. Microorganisms. 2022 Jul 31;10(8):1552. doi: 10.3390/microorganisms10081552. PMID: 36013970; PMCID: PMC9414836.
80. Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, Hall MD. Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19. ACS Cent Sci. 2020 May 27;6(5):672-683. doi: 10.1021/acscentsci.0c00489. Epub 2020 May 4. Erratum in: ACS Cent Sci. 2020 Jun 24;6(6):1009. doi: 10.1021/acscentsci.0c00747. PMID: 32483554; PMCID: PMC7202249.
81. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC; ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020 Nov 5;383(19):1813-1826. doi: 10.1056/NEJMoa2007764. Epub 2020 Oct 8. PMID: 32445440; PMCID: PMC7262788.
82. Petrova VN, Russell CA. The evolution of seasonal influenza viruses. Nat Rev Microbiol. 2018 Jan;16(1):47-60. doi: 10.1038/nrmicro.2017.118. Epub 2017 Oct 30. Erratum in: Nat Rev Microbiol. 2018 Jan;16(1):60. doi: 10.1038/nrmicro.2017.146. PMID: 29081496.
83. Chua KB, Bellini WJ, Rota PA, Harcourt BH, Tamin A, Lam SK, Ksiazek TG, Rollin PE, Zaki SR, Shieh W, Goldsmith CS, Gubler DJ, Roehrig JT, Eaton B, Gould AR, Olson J, Field H, Daniels P, Ling AE, Peters CJ, Anderson LJ, Mahy BW. Nipah virus: a recently emergent deadly paramyxovirus. Science. 2000 May 26;288(5470):1432-5. doi: 10.1126/science.288.5470.1432. PMID: 10827955.
84. Mulangu S, Dodd LE, Davey RT Jr, Tshiani Mbaya O, Proschan M, Mukadi D, Lusakibanza Manzo M, Nzolo D, Tshomba Oloma A, Ibanda A, Ali R, Coulibaly S, Levine AC, Grais R, Diaz J, Lane HC, Muyembe-Tamfum JJ; PALM Writing Group; Sivahera B, Camara M, Kojan R, Walker R, Dighero-Kemp B, Cao H, Mukumbayi P, Mbala-Kingebeni P, Ahuka S, Albert S, Bonnett T, Crozier I, Duvenhage M, Proffitt C, Teitelbaum M, Moench T, Aboulhab J, Barrett K, Cahill K, Cone K, Eckes R, Hensley L, Herpin B, Higgs E, Ledgerwood J, Pierson J, Smolskis M, Sow Y, Tierney J, Sivapalasingam S, Holman W, Gettinger N, Vallée D, Nordwall J; PALM Consortium Study Team. A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. N Engl J Med. 2019 Dec 12;381(24):2293-2303. doi:

10.1056/NEJMoa1910993. Epub 2019 Nov 27. PMID: 31774950; PMCID: PMC10680050.

85. PREVAIL II Writing Group; Multi-National PREVAIL II Study Team; Davey RT Jr, Dodd L, Proschan MA, Neaton J, Neuhaus Nordwall J, Koopmeiners JS, Beigel J, Tierney J, Lane HC, Fauci AS, Massaquoi MBF, Sahr F, Malvy D. A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection. N Engl J Med. 2016 Oct 13;375(15):1448-1456. doi: 10.1056/NEJMoa1604330. PMID: 27732819; PMCID: PMC5086427.
86. Lü Z, Dai X, Xu J, Liu Z, Guo Y, Gao Z, Meng F. Medicinal chemistry strategies toward broad-spectrum antiviral agents to prevent next pandemics. Eur J Med Chem. 2024 May 5;271:116442. doi: 10.1016/j.ejmech.2024.116442. Epub 2024 Apr 25. PMID: 38685143.
87. Kalepu, S., & Nekkanti, V. (2015). Insoluble drug delivery strategies: review of recent advances and business prospects. Acta Pharmaceutica Sinica B, 5(5), 442–453. https://doi.org/10.1016/j.apsb.2015.07.003
88. Ben-Zuk N, Dechtman ID, Henn I, Weiss L, Afriat A, Krasner E, Gal Y. Potential Prophylactic Treatments for COVID-19. Viruses. 2021 Jul 2;13(7):1292. doi: 10.3390/v13071292. PMID: 34372498; PMCID: PMC8310088.
89. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: New estimates of R&D costs. J Health Econ. 2016 May;47:20-33. doi: 10.1016/j.jhealeco.2016.01.012. Epub 2016 Feb 12. PMID: 26928437.
90. Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MDP, Acosta-Torres LS, Diaz-Torres LA, Grillo R, Swamy MK, Sharma S, Habtemariam S, Shin HS. Nano-based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 2018 Sep 19;16(1):71. doi: 10.1186/s12951-018-0392-8. PMID: 30231877; PMCID: PMC6145203.
91. Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S, Romero DA, Horvath P. CRISPR provides acquired resistance against viruses in prokaryotes. Science. 2007 Mar 23;315(5819):1709-12. doi: 10.1126/science.1138140. PMID: 17379808.
92. Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A, Kim RB, Roden DM, Stein CM. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med. 2008 Mar 6;358(10):999-1008. doi: 10.1056/NEJMoa0708078. PMID: 18322281; PMCID: PMC3894627.
93. Gopakumar, G., Diaz-Méndez, A., Coppo, M. J. C., Hartley, C. A., & Devlin, J. M. (2024). Transcriptomic analyses of host-virus interactions during in vitro infection with wild-type and glycoprotein g-deficient (ΔgG) strains of ILTV in primary and continuous cell cultures. *PLoS ONE*, *19*(10), e0311874. https://doi.org/10.1371/journal.pone.0311874
94. Kamelian K, Montoya V, Olmstead A, Dong W, Harrigan R, Morshed M, Joy JB. Phylogenetic surveillance of travel-related Zika virus infections through whole-genome sequencing methods. Sci Rep. 2019 Nov 11;9(1):16433. doi: 10.1038/s41598-019-52613-8. PMID: 31712570; PMCID: PMC6848190.

